The presence of this predictive factor qualify NSCLC patients to first-line therapy with the use of pembrolizumab or atezolizumab (recently pembrolizumab in monotherapy can also be used in patients with PD-L1 expression on ≥ 1% of tumor cells). The gene discussed is CD274; the disease is neoplasm.